Immunovant (IMVT) Competitors

$27.84 -0.01 (-0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$27.98 +0.14 (+0.52%)

As of 07:57 PM Eastern

IMVT vs. SLNO, MRNA, ROIV, GMAB, and SMMT

Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Moderna (MRNA), Roivant Sciences (ROIV), Genmab A/S (GMAB), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector.

How does Immunovant compare to Soleno Therapeutics?

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

: Immunovant currently has a consensus target price of $32.44, indicating a potential upside of 16.54%. Soleno Therapeutics has a consensus target price of $76.67, indicating a potential upside of 44.87%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
4 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.45
Soleno Therapeutics
1 Sell rating(s)

9 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.15
: Immunovant has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.22, indicating that its share price is 322% less volatile than the S&P 500.
: Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunovant N/A N/A -$413.84M -$2.69 N/A
Soleno Therapeutics $190.40M 14.49 $20.89M $0.23 230.09
: Soleno Therapeutics' return on equity of 5.90% beat Immunovant's return on equity.
Company Net Margins Return on Equity Return on Assets
Immunovant N/A -63.17% -58.01%
Soleno Therapeutics N/A 5.90% 4.61%
: In the previous week, Soleno Therapeutics had 31 more articles in the media than Immunovant. MarketBeat recorded 38 mentions for Soleno Therapeutics and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.92 beat Soleno Therapeutics' score of 0.11 indicating that Immunovant is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Soleno Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
31 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
: 47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Soleno Therapeutics	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.15

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A
Soleno Therapeutics	$190.40M	14.49	$20.89M	$0.23	230.09

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-63.17%	-58.01%
Soleno Therapeutics	N/A	5.90%	4.61%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soleno Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Soleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks.

How does Immunovant compare to Moderna?

Moderna (NASDAQ:MRNA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

: Moderna currently has a consensus target price of $35.73, indicating a potential downside of 23.50%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 16.54%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Moderna.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
5 Sell rating(s)
12 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.84
Immunovant
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.45
: Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
: Immunovant has lower revenue, but higher earnings than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Moderna $1.94B 9.49 -$2.82B -$8.15 N/A
Immunovant N/A N/A -$413.84M -$2.69 N/A
: Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity.
Company Net Margins Return on Equity Return on Assets
Moderna -143.55% -26.64% -19.32%
Immunovant N/A -63.17% -58.01%
: In the previous week, Moderna had 46 more articles in the media than Immunovant. MarketBeat recorded 53 mentions for Moderna and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.92 beat Moderna's score of 0.04 indicating that Immunovant is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
19 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
8 Negative mention(s)
5 Very Negative mention(s)
Neutral
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 75.3% of Moderna shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.49	-$2.82B	-$8.15	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Immunovant	N/A	-63.17%	-58.01%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	5 Very Negative mention(s)	Neutral
Immunovant	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Moderna and Immunovant tied by winning 7 of the 14 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

: 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
: In the previous week, Roivant Sciences had 1 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Roivant Sciences and 7 mentions for Immunovant. Roivant Sciences' average media sentiment score of 1.26 beat Immunovant's score of 0.92 indicating that Roivant Sciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Immunovant's return on equity.
Company Net Margins Return on Equity Return on Assets
Roivant Sciences -6,079.94% -19.04% -18.15%
Immunovant N/A -63.17% -58.01%
: Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Roivant Sciences $29.05M 697.72 -$171.98M -$1.17 N/A
Immunovant N/A N/A -$413.84M -$2.69 N/A
: Roivant Sciences currently has a consensus target price of $30.55, indicating a potential upside of 7.87%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 16.54%. Given Immunovant's higher possible upside, analysts plainly believe Immunovant is more favorable than Roivant Sciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
1 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.75
Immunovant
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.45

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Immunovant	N/A	-63.17%	-58.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	697.72	-$171.98M	-$1.17	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Roivant Sciences beats Immunovant on 12 of the 14 factors compared between the two stocks.

How does Immunovant compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

: 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
: In the previous week, Genmab A/S had 7 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Genmab A/S and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.92 beat Genmab A/S's score of 0.72 indicating that Immunovant is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Genmab A/S has a net margin of 25.89% compared to Immunovant's net margin of 0.00%. Genmab A/S's return on equity of 17.35% beat Immunovant's return on equity.
Company Net Margins Return on Equity Return on Assets
Genmab A/S 25.89% 17.35% 11.69%
Immunovant N/A -63.17% -58.01%
: Genmab A/S has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
Immunovant N/A N/A -$413.84M -$2.69 N/A
: Genmab A/S presently has a consensus target price of $39.07, indicating a potential upside of 41.94%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 16.54%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Immunovant.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
Immunovant
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.45

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	25.89%	17.35%	11.69%
Immunovant	N/A	-63.17%	-58.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Genmab A/S beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

: Summit Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A
Immunovant N/A N/A -$413.84M -$2.69 N/A
: Summit Therapeutics has a beta of -1.25, meaning that its stock price is 225% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
: Summit Therapeutics presently has a consensus target price of $27.58, indicating a potential upside of 57.26%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 16.54%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Summit Therapeutics is more favorable than Immunovant.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
2 Sell rating(s)
5 Hold rating(s)

8 Buy rating(s)

2 Strong Buy rating(s)
2.59
Immunovant
1 Sell rating(s)

4 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.45
: 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, Summit Therapeutics had 13 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Summit Therapeutics and 7 mentions for Immunovant. Immunovant's average media sentiment score of 0.92 beat Summit Therapeutics' score of 0.19 indicating that Immunovant is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Immunovant's return on equity of -63.17% beat Summit Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Summit Therapeutics N/A -291.24% -243.07%
Immunovant N/A -63.17% -58.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Immunovant	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Immunovant	N/A	-63.17%	-58.01%

Summary

Summit Therapeutics beats Immunovant on 7 of the 13 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.67B	$3.39B	$6.24B	$11.86B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	N/A	38.85	29.04	28.48
Price / Sales	N/A	157.28	477.10	60.43
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	6.69	7.03	9.67	6.67
Net Income	-$413.84M	$23.62M	$3.55B	$332.64M
7 Day Performance	3.15%	3.67%	1.70%	2.01%
1 Month Performance	13.63%	7.17%	5.62%	9.19%
1 Year Performance	82.92%	67.04%	34.42%	39.59%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	2.1587 of 5 stars	$27.84 0.0%	$32.44 +16.5%	N/A	$5.67B	N/A	N/A	120
SLNO Soleno Therapeutics	4.1787 of 5 stars	$52.75 +0.1%	$76.67 +45.3%	N/A	$2.72B	$190.40M	229.36	30	Trending News Upcoming Earnings
MRNA Moderna	1.138 of 5 stars	$48.70 -4.0%	$33.87 -30.5%	N/A	$20.04B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
ROIV Roivant Sciences	2.8134 of 5 stars	$27.85 +1.6%	$30.55 +9.7%	N/A	$19.62B	$13.31M	N/A	860	Positive News
GMAB Genmab A/S	4.7211 of 5 stars	$26.64 -0.9%	$39.36 +47.7%	N/A	$17.26B	$3.72B	17.19	3,029	Positive News Upcoming Earnings Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. SLNO, MRNA, ROIV, GMAB, and SMMT

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to Moderna?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Genmab A/S?

Summary

How does Immunovant compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. SLNO, MRNA, ROIV, GMAB, and SMMT

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to Moderna?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Genmab A/S?

Summary

How does Immunovant compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools